<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DVR</journal-id>
<journal-id journal-id-type="hwp">spdvr</journal-id>
<journal-title>Diabetes &amp; Vascular Disease Research</journal-title>
<issn pub-type="ppub">1479-1641</issn>
<issn pub-type="epub">1752-8984</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1479164113490179</article-id>
<article-id pub-id-type="publisher-id">10.1177_1479164113490179</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Adiponectin in coronary heart disease and newly diagnosed impaired glucose tolerance</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Azizi Ghanbari</surname><given-names>Aline</given-names></name>
<xref ref-type="aff" rid="aff1-1479164113490179">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dörr</surname><given-names>Rolf</given-names></name>
<xref ref-type="aff" rid="aff3-1479164113490179">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Spitzer</surname><given-names>Stefan</given-names></name>
<xref ref-type="aff" rid="aff3-1479164113490179">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stumpf</surname><given-names>Juergen</given-names></name>
<xref ref-type="aff" rid="aff3-1479164113490179">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Britz</surname><given-names>Andreas</given-names></name>
<xref ref-type="aff" rid="aff2-1479164113490179">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Amann-Zalan</surname><given-names>Ildiko</given-names></name>
<xref ref-type="aff" rid="aff4-1479164113490179">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lodwig</surname><given-names>Volker</given-names></name>
<xref ref-type="aff" rid="aff4-1479164113490179">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ulm</surname><given-names>Bernhard</given-names></name>
<xref ref-type="aff" rid="aff5-1479164113490179">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schnell</surname><given-names>Oliver</given-names></name>
<xref ref-type="aff" rid="aff5-1479164113490179">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lohmann</surname><given-names>Tobias</given-names></name>
<xref ref-type="aff" rid="aff1-1479164113490179">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1479164113490179"><label>1</label>Department of Medicine, Municipal Hospital of Dresden-Neustadt, Dresden, Germany</aff>
<aff id="aff2-1479164113490179"><label>2</label>Central Laboratory, Municipal Hospital of Dresden-Neustadt, Dresden, Germany</aff>
<aff id="aff3-1479164113490179"><label>3</label>Praxisklinik Herz und Gefässe, Dresden, Germany</aff>
<aff id="aff4-1479164113490179"><label>4</label>Roche Diagnostics GmbH, Mannheim, Germany</aff>
<aff id="aff5-1479164113490179"><label>5</label>Diabetes Research Group at the Helmholtz Center, Munich, Germany</aff>
<author-notes>
<corresp id="corresp1-1479164113490179">Tobias Lohmann, Department of Medicine, Municipal Hospital of Dresden-Neustadt, Industriestr. 40, 01129 Dresden, Germany. Email: <email>tobias.lohmann@khdn.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>5</issue>
<fpage>452</fpage>
<lpage>458</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1479164113490179">
<title>Objective:</title>
<p>Adiponectin is produced by adipose tissue and regarded as protective hormone for diabetes and coronary heart disease (CHD). Its role in heart failure is discussed controversially.</p>
</sec>
<sec id="section2-1479164113490179">
<title>Methods:</title>
<p>In this study, 1015 consecutive patients admitted for acute (<italic>n</italic> = 149) or elective (<italic>n</italic> = 866) coronary angiography were enrolled. Patients with known diabetes mellitus (DM) were excluded. All patients were classified by oral glucose tolerance test (oGTT) according to World Health Organization (WHO) criteria and by the results of coronary angiography as no/minor coronary heart disease (CHD), single-vessel disease (1-VD), double-vessel disease (2-VD) or triple-vessel disease (3-VD), by New York Heart Association (NYHA) criteria and by echocardiography for heart failure. Adiponectin and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were measured in all patients.</p>
</sec>
<sec id="section3-1479164113490179">
<title>Results:</title>
<p>Adiponectin was higher in patients with normal glucose tolerance (NGT) (13.65 ± 10.31 mg/l) compared to impaired glucose tolerance (IGT) (11.12 ± 7.5, <italic>p</italic> &lt; 0.001) or diabetes (11.22 ± 7.63, <italic>p</italic> &lt; 0.001). There was a stepwise decrease in adiponectin from no CHD (18.16 ± 12.49 mg/L) to minor CHD (16.01 ± 11.42) to 1-VD (12.18 ± 8.8, <italic>p</italic> &lt; 0.001 to no/minor CHD) to 2- and 3-VD (10.68 ± 7.5, <italic>p</italic> &lt; 0.001 to no/minor CHD, <italic>p</italic> = 0.004 to 1-VD). Patients with heart failure NYHA III (17.4 ± 10.27) had higher adiponectin levels compared to NYHA II (12.94 ± 9.41, <italic>p</italic> &lt; 0.001 to NYHA III) and NYHA I (10.3 ± 7.75, <italic>p</italic> &lt; 0.001 to NYHA III/II). In this line, adiponectin levels were positively correlated to NT-proBNP levels (<italic>r</italic> = 0.303), and patients with ejection fraction (EF) &lt; 50% had higher adiponectin levels than those with EF &gt; 50% (14.96 ± 4.35 to 11.78 ± 3.71, <italic>p</italic> = 0.006).</p>
</sec>
<sec id="section4-1479164113490179">
<title>Conclusion:</title>
<p>Adiponectin levels are inversely correlated to progressing CHD and glucose intolerance but positively correlated to increasing heart failure.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Adiponectin</kwd>
<kwd>coronary heart disease</kwd>
<kwd>diabetes mellitus</kwd>
<kwd>heart failure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1479164113490179" sec-type="intro">
<title>Introduction</title>
<p>Adiponectin is an adipocyte-secreted protein associated with insulin resistance, increased body weight and cardiovascular dysfunction and may have anti-inflammatory properties.<sup><xref ref-type="bibr" rid="bibr1-1479164113490179">1</xref></sup> It was originally identified by four independent groups and also called as Acrp30, GBP28, apM1 and AdipoQ.<sup><xref ref-type="bibr" rid="bibr2-1479164113490179">2</xref><xref ref-type="bibr" rid="bibr3-1479164113490179"/><xref ref-type="bibr" rid="bibr4-1479164113490179"/>–<xref ref-type="bibr" rid="bibr5-1479164113490179">5</xref></sup> Low adiponectin levels predict future risk of developing type 2 diabetes.<sup><xref ref-type="bibr" rid="bibr6-1479164113490179">6</xref></sup> Moreover, adiponectin levels are decreased in patients with coronary heart disease (CHD),<sup><xref ref-type="bibr" rid="bibr7-1479164113490179">7</xref></sup> and high adiponectin levels predict a lower risk of future myocardial infarction.<sup><xref ref-type="bibr" rid="bibr8-1479164113490179">8</xref></sup> However, high adiponectin levels are surprisingly associated with increased risk of recurrent cardiovascular events<sup><xref ref-type="bibr" rid="bibr9-1479164113490179">9</xref></sup> and mortality in patients with myocardial infarction<sup><xref ref-type="bibr" rid="bibr10-1479164113490179">10</xref></sup> and heart failure.<sup><xref ref-type="bibr" rid="bibr11-1479164113490179">11</xref><xref ref-type="bibr" rid="bibr12-1479164113490179"/>–<xref ref-type="bibr" rid="bibr13-1479164113490179">13</xref></sup> Therefore, it may be difficult to use adiponectin levels in individual patients to predict risk of cardiovascular disease or mortality.</p>
<p>We have investigated a large cohort (<italic>n</italic> &gt; 1000) of unselected patients admitted to coronary catheterization without known diabetes. All patients were clinically well characterized, exactly stated for coronary findings and underwent standardized oral glucose tolerance test (oGTT). We looked whether adiponectin levels correlated to (1) glucose dysregulation in this early stage of disease, (2) extent of coronary disease in catheterization and (3) extent of cardiac dysfunction defined by New York Heart Association (NYHA) state, ejection fraction (EF) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.</p>
</sec>
<sec id="section6-1479164113490179">
<title>Research design and methods</title>
<sec id="section7-1479164113490179">
<title>Study population</title>
<p>In this study, 1015 consecutive patients admitted for coronary catheterization to the ‘Praxisklinik Herz und Gefässe’, Dresden, Germany, from June 2007 to June 2009 were included. Altogether, 149 patients were admitted for acute coronary syndrome and 866 patients for routine catheterization. Data on patients are published elsewhere.<sup><xref ref-type="bibr" rid="bibr14-1479164113490179">14</xref></sup> In summary, 319 patients were female, mean age was 68.2 years and mean body mass index (BMI) was 27.4 kg/m<sup>2</sup>. Patients with known diabetes mellitus (DM) were excluded as were patients with known endocrine, pancreatic, hepatic or chronic kidney diseases [estimated glomerular filtration rate (eGFR) &lt; 50 mL/min]. All patients provided written consent, and the study was performed in accordance with the Declaration of Helsinki (approval by the local ethics committee, Sächsische Ärztekammer registration no. EK-BR-36/06-1).</p>
<p>After oGTT, patients were classified as follows: with normal glucose tolerance (NGT) (<italic>n</italic> = 513), with impaired fasting glucose (IFG) (<italic>n</italic> = 10), with impaired glucose tolerance (IGT) (<italic>n</italic> = 349) and with DM (<italic>n</italic> = 143). For analysis, the groups with IFG and IGT were summarized as one group due to the small number of patients with IFG. After catheterization, patients were classified as no CHD (<italic>n</italic> = 63), minor CHD (<italic>n</italic> = 183), single-vessel disease (1-VD) (<italic>n</italic> = 222), double-vessel disease (2-VD) (<italic>n</italic> = 225) and triple-vessel disease (3-VD) (<italic>n</italic> = 322). For analysis, the groups of 2-VD and 3-VD were summarized as multiple-VD. Heart failure was defined clinically by NYHA classification: NYHA I (<italic>n</italic> = 324), NYHA II (<italic>n</italic> = 566) and NYHA III (<italic>n</italic> = 63). Nearly all (999/1015) the patients also had echocardiography with estimation of EF.</p>
</sec>
<sec id="section8-1479164113490179">
<title>Laboratory analyses</title>
<p>All patients underwent an oGTT on the day after the coronary angiography. After an overnight fast for at least 10 h, a standard oGTT (75 g of glucose in 250 mL of water) was performed between 8:00 a.m. and 10:00 a.m. according to World Health Organization (WHO) recommendations.<sup><xref ref-type="bibr" rid="bibr15-1479164113490179">15</xref></sup> The diagnosis of diabetes according to the oGTT results was based on the WHO Consulting Group Criteria:<sup><xref ref-type="bibr" rid="bibr15-1479164113490179">15</xref></sup> venous fasting plasma glucose (FPG) ≥ 126 mg/dL (7 mmol/L) and/or 2-h post-load plasma glucose after an oGTT ≥ 200 mg/dL (11.1 mmol/L).<sup><xref ref-type="bibr" rid="bibr15-1479164113490179">15</xref></sup> IGT was defined as FPG &lt; 126 mg/dL (7.0 mmol/L) and 2-h post-load plasma glucose ≥ 140 mg/dL (7.8 mmol/L) and &lt;200 mg/dL (11.1 mmol/L) by WHO criteria.<sup><xref ref-type="bibr" rid="bibr15-1479164113490179">15</xref></sup> IFG was defined as FPG ≥ 100 mg/dL (5.6 mmol/L) and FPG &lt; 126 mg/dL (7 mmol/L) using American Diabetes Association (ADA) criteria.<sup><xref ref-type="bibr" rid="bibr16-1479164113490179">16</xref></sup> NGT was defined as FPG &lt; 100 mg/dL (5.6 mmol/L) and 2-h post-load plasma glucose &lt; 140 mg/dL (7.8 mmol/L) by WHO criteria.<sup><xref ref-type="bibr" rid="bibr15-1479164113490179">15</xref></sup></p>
<p>Plasma glucose, HbA<sub>1c</sub>, lipid levels, creatinine, electrolytes, blood count, lipids and C-reactive protein were analysed in the Central Laboratory of the Municipal Hospital of Dresden-Neustadt by routine methods. Whole adiponectin was measured by enzyme-linked immunosorbent assay (ELISA) kit purchased from Mediagnost GmbH, and NT-proBNP was measured by Enzyme Light Fluorescence Assay of Roche Diagnostics GmbH. Adiponectin levels are demonstrated as mean ± standard deviation (SD) in text and median + 25/75 and 10/90 percentiles in <xref ref-type="fig" rid="fig1-1479164113490179">Figures 1</xref> to <xref ref-type="fig" rid="fig4-1479164113490179">4</xref>.</p>
<fig id="fig1-1479164113490179" position="float">
<label>Figure 1.</label>
<caption>
<p>Adiponectin and glucose tolerance. Adiponectin levels in patients with normal glucose tolerance (NGT), impaired glucose tolerance [IGT, including patients with impaired fasting glucose (IFG), see ‘Research design and methods’ section] and patients with diabetes mellitus (DM).</p>
<p>Values are shown as median, 25th and 75th percentiles in boxes, 10th and 90th percentiles in lines, outliers as circles and extreme outliers as asterisks.</p>
</caption>
<graphic xlink:href="10.1177_1479164113490179-fig1.tif"/>
</fig>
<fig id="fig2-1479164113490179" position="float">
<label>Figure 2.</label>
<caption>
<p>Adiponectin and stage of coronary heart disease. Adiponectin levels in patients with no coronary heart disease (no CHD), minor coronary heart disease (minor CHD), single-vessel disease (1-VD) and double- or triple-vessel disease (2- or 3-VD).</p>
<p>Values are shown as median, 25th and 75th percentiles in boxes, 10th and 90th percentiles in lines, outliers as circles and extreme outliers as asterisks.</p>
</caption>
<graphic xlink:href="10.1177_1479164113490179-fig2.tif"/>
</fig>
<fig id="fig3-1479164113490179" position="float">
<label>Figure 3.</label>
<caption><p>Adiponectin and NYHA state of heart failure. Adiponectin levels in patients with NYHA states I, II and III as indicated.</p>
<p>NYHA: New York Heart Association.</p>
<p>Values are shown as median, 25th and 75th percentiles in boxes, 10th and 90th percentiles in lines, outliers as circles and extreme outliers as asterisks.</p>
</caption>
<graphic xlink:href="10.1177_1479164113490179-fig3.tif"/>
</fig>
<fig id="fig4-1479164113490179" position="float">
<label>Figure 4.</label>
<caption><p>Adiponectin and ejection fraction in echocardiography. Adiponectin levels in patients with ejection fraction (EF) &lt; 50% and &gt; 50% in echocardiography as indicated.</p>
<p>Values are shown as median, 25th and 75th percentiles in boxes, 10th and 90th percentiles in lines, outliers as circles and extreme outliers as asterisks.</p>
</caption>
<graphic xlink:href="10.1177_1479164113490179-fig4.tif"/>
</fig>
</sec>
<sec id="section9-1479164113490179">
<title>Coronary angiography</title>
<p>Coronary angiography was performed by the Judkins method or modified Sones technique with direct puncture of either brachial or radial artery in the catheterization laboratory of the Praxisklinik Herz und Gefaesse, Dresden. CHD was defined based on the results of the coronary angiography as follows – no CHD: normal luminal diameter of any coronary artery, minor CHD: &lt;50% stenosis of any coronary artery, 1-VD: &gt;50% of any coronary artery disease, 2-VD: &gt;50% stenosis of two different main coronary arteries and 3-VD: &gt;50% stenosis of three different main coronary arteries. Coronary angiography findings were classified by independent visual assessment of two experienced interventional cardiologists and, at the 50% diameter stenosis threshold, by computer-based quantitative coronary angiography (QCA) as follows: no angiographic evidence of obstructive CHD, minor CHD with lesions of &lt;50% diameter narrowing, 1-VD, 2-VD or 3-VD.<sup><xref ref-type="bibr" rid="bibr17-1479164113490179">17</xref></sup></p>
</sec>
<sec id="section10-1479164113490179">
<title>Statistical methods</title>
<p>Because of the sample size, a normal distribution of the means could be assumed; the analysis of variance (ANOVA) with the Tukey–Kramer post hoc test and the student’s <italic>t</italic>-test were used to compare adiponectin levels between patient groups. A <italic>p</italic> value of 0.05 was regarded as significant. In <xref ref-type="fig" rid="fig1-1479164113490179">Figures 1</xref> to <xref ref-type="fig" rid="fig4-1479164113490179">4</xref>, outliers are shown and are defined by a distance greater than 1.5-fold (outlier) or 3-fold (extreme outlier) of the interquartile range between 25th and 75th quartiles. All outliers were included into the statistical analysis. Furthermore, correlation between adiponectin and NT-proBNP levels was tested by Pearson method. By multivariate logistic regression model, we have controlled whether the correlation of adiponectin levels to glucose tolerance state; the extent of coronary disease and state of heart failure were independent of possible confounders such as age, sex and other known cardiovascular risk factors. SPSS version 14 for Windows was used for statistical analysis.</p>
</sec>
</sec>
<sec id="section11-1479164113490179" sec-type="results">
<title>Results</title>
<sec id="section12-1479164113490179">
<title>Adiponectin and glucose tolerance</title>
<p>Adiponectin was higher in patients with NGT (13.65 ± 10.31 mg/L) compared to IFG/IGT (11.12 ± 7.5 mg/L, <italic>p</italic> &lt; 0.001 to NGT) or DM (11.22 ± 7.63 mg/L, <italic>p</italic> &lt; 0.001 to NGT, non-significant to IFG/IGT) (<xref ref-type="fig" rid="fig1-1479164113490179">Figure 1</xref>). There was no significant difference in adiponectin levels in elective (12.62 ± 9.29 mg/L) compared to acute investigated patients (11.25 ± 8.04 mg/L).</p>
</sec>
<sec id="section13-1479164113490179">
<title>Adiponectin and CHD</title>
<p>There was a stepwise decrease in adiponectin levels from no CHD (18.16 ± 12.49 mg/L) to minimal CHD (16.01 ± 11.42 mg/L, non-significant to no CHD) to 1-VD (12.18 ± 8.8 mg/L, <italic>p</italic> &lt; 0.001 to no and minimal CHD) and to 2- and 3-VD (10.68 ± 7.5 mg/L, <italic>p</italic> &lt; 0.001 to no and minor CHD, <italic>p</italic> = 0.004 to 1-VD) (<xref ref-type="fig" rid="fig2-1479164113490179">Figure 2</xref>).</p>
</sec>
<sec id="section14-1479164113490179">
<title>Adiponectin and heart failure</title>
<p>Patients with heart failure NYHA III (17.4 ± 10.27 mg/L) had higher adiponectin levels compared to patients with NYHA II (12.94 ± 9.41 mg/L, <italic>p</italic> &lt; 0.001 to NYHA III) and NYHA I (10.3 ± 7.75 mg/L, <italic>p</italic> &lt; 0.001 to NYHA III and II) (<xref ref-type="fig" rid="fig3-1479164113490179">Figure 3</xref>). Moreover, adiponectin levels were positively correlated to NT-proBNP levels (<italic>r</italic> = 0.303, <italic>p</italic> &lt; 0.001). Patients with EF &lt; 50% had higher adiponectin levels (14.96 ± 4.35 mg/L) compared to patients with EF ≥ 50% (11.78 ± 3.71 mg/L, <italic>p</italic> = 0.006) (<xref ref-type="fig" rid="fig4-1479164113490179">Figure 4</xref>).</p>
</sec>
<sec id="section15-1479164113490179">
<title>Correlation of adiponectin with known risk factors of cardiovascular disease</title>
<p>We found a positive correlation of adiponectin to whole cholesterol (<italic>r</italic> = 0.204, <italic>p</italic> &lt; 0.001), high-density lipoprotein (HDL) cholesterol (<italic>r</italic> = 0.473, <italic>p</italic> &lt; 0.001) and low-density lipoprotein (LDL) cholesterol (<italic>r</italic> = 0.176, <italic>p</italic> &lt; 0.001) and a negative correlation to triglycerides (<italic>r</italic> = −0.247, <italic>p</italic> &lt; 0.001). There was no difference in adiponectin levels between patients with and without hypertension or patients with and without family history of CHD, but smokers had lower levels of adiponectin than non-smokers (both for actual and ever smoking, <italic>p</italic> &lt; 0.001 compared to never smoking), and patients with normal body weight (BMI &lt; 25) had higher adiponectin levels (13.95 ± 9.73 mg/L) compared to patients with overweight (BMI = 25.0–29.9, adiponectin = 12.0 ± 9.25 mg/L, <italic>p</italic> = 0.004) and <italic>adipositas</italic> (BMI ≥ 30, adiponectin = 11.55 ± 7.69 mg/L, <italic>p</italic> = 0.015).</p>
<p>As adiponectin levels differ according to gender (men = 9.99 ± 6.71, women = 17.81 ± 11.23, <italic>p</italic> &lt; 0.0001), the regression analysis was performed overall and split into men and women. Multivariate binary regression analysis shows that for IGT compared to NGT, adiponectin levels, age and BMI showed significant results in all three analysis [for odds ratio (OR), see <xref ref-type="table" rid="table1-1479164113490179">Table 1</xref>]. Neither HDL nor creatinine revealed a significant influence in any group. Triglyceride was significant in the overall regression but not in the gender-specific calculations. Diabetes compared to NGT showed significant results in terms of age and triglyceride for all groups. HDL and creatinine had no significance in any group. Adiponectin was only significant in the female population, and BMI was significant in the overall comparison and in the male group. For extent of coronary disease, 1-VD compared to no CHD, no factor had a significant influence in all three groups. Age was significant in the overall and in the female group, and adiponectin and creatinine were significant only in the overall group. In comparison between 2-VD/3-VD and no CHD for all patients, adiponectin, age, HDL and creatinine appeared as significant influences. Adiponectin was the only significant factor in men, and age and HDL were the significant factors in female patients (for OR, see <xref ref-type="table" rid="table2-1479164113490179">Table 2</xref>).</p>
<table-wrap id="table1-1479164113490179" position="float">
<label>Table 1.</label>
<caption>
<p>Adiponectin dependence from glucose tolerance (IGT/IFG or DM compared to NGT).</p>
</caption>
<graphic alternate-form-of="table1-1479164113490179" xlink:href="10.1177_1479164113490179-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="4">Overall<hr/></th>
<th align="left" colspan="4">Male<hr/></th>
<th align="left" colspan="4">Female<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for odds ratio<hr/></th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for odds ratio<hr/></th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for odds ratio<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="7">IFG and IGT</td>
<td>Intercept</td>
<td colspan="4">0.000</td>
<td colspan="4">0.000</td>
<td colspan="4">0.001</td>
</tr>
<tr>
<td>Adiponectin</td>
<td><bold>0.000</bold></td>
<td>0.965</td>
<td>0.946</td>
<td>0.984</td>
<td><bold>0.022</bold></td>
<td>0.966</td>
<td>0.937</td>
<td>0.995</td>
<td><bold>0.004</bold></td>
<td>0.954</td>
<td>0.925</td>
<td>0.985</td>
</tr>
<tr>
<td>Age</td>
<td>0.000</td>
<td>1.040</td>
<td>1.022</td>
<td>1.058</td>
<td>0.009</td>
<td>1.028</td>
<td>1.007</td>
<td>1.050</td>
<td>0.000</td>
<td>1.067</td>
<td>1.031</td>
<td>1.104</td>
</tr>
<tr>
<td>BMI</td>
<td>0.000</td>
<td>1.071</td>
<td>1.032</td>
<td>1.112</td>
<td>0.007</td>
<td>1.070</td>
<td>1.019</td>
<td>1.123</td>
<td>0.024</td>
<td>1.072</td>
<td>1.009</td>
<td>1.139</td>
</tr>
<tr>
<td>HDL</td>
<td>0.346</td>
<td>0.814</td>
<td>0.531</td>
<td>1.248</td>
<td>0.510</td>
<td>0.842</td>
<td>0.505</td>
<td>1.404</td>
<td>0.362</td>
<td>0.679</td>
<td>0.295</td>
<td>1.560</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.033</td>
<td>1.250</td>
<td>1.019</td>
<td>1.534</td>
<td>0.087</td>
<td>1.213</td>
<td>0.972</td>
<td>1.514</td>
<td>0.413</td>
<td>1.259</td>
<td>0.726</td>
<td>2.185</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.180</td>
<td>1.003</td>
<td>0.999</td>
<td>1.007</td>
<td>0.132</td>
<td>1.004</td>
<td>0.999</td>
<td>1.010</td>
<td>0.750</td>
<td>0.998</td>
<td>0.985</td>
<td>1.011</td>
</tr>
<tr>
<td rowspan="7">DM</td>
<td>Intercept</td>
<td colspan="4">0.000</td>
<td colspan="4">0.000</td>
<td colspan="4">0.000</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>0.071</td>
<td>0.975</td>
<td>0.949</td>
<td>1.002</td>
<td>0.647</td>
<td>0.991</td>
<td>0.953</td>
<td>1.030</td>
<td><bold>0.027</bold></td>
<td>0.950</td>
<td>0.907</td>
<td>0.994</td>
</tr>
<tr>
<td>Age</td>
<td>0.000</td>
<td>1.052</td>
<td>1.027</td>
<td>1.079</td>
<td>0.010</td>
<td>1.039</td>
<td>1.009</td>
<td>1.070</td>
<td>0.004</td>
<td>1.076</td>
<td>1.024</td>
<td>1.130</td>
</tr>
<tr>
<td>BMI</td>
<td>0.017</td>
<td>1.064</td>
<td>1.011</td>
<td>1.120</td>
<td>0.039</td>
<td>1.070</td>
<td>1.003</td>
<td>1.141</td>
<td>0.331</td>
<td>1.044</td>
<td>0.957</td>
<td>1.140</td>
</tr>
<tr>
<td>HDL</td>
<td>0.367</td>
<td>0.750</td>
<td>0.401</td>
<td>1.402</td>
<td>0.200</td>
<td>0.601</td>
<td>0.276</td>
<td>1.308</td>
<td>0.476</td>
<td>1.523</td>
<td>0.479</td>
<td>4.843</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.000</td>
<td>1.858</td>
<td>1.460</td>
<td>2.365</td>
<td>0.000</td>
<td>1.658</td>
<td>1.275</td>
<td>2.156</td>
<td>0.000</td>
<td>3.308</td>
<td>1.694</td>
<td>6.459</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.904</td>
<td>1.000</td>
<td>0.992</td>
<td>1.007</td>
<td>0.991</td>
<td>1.000</td>
<td>0.991</td>
<td>1.010</td>
<td>0.900</td>
<td>1.001</td>
<td>0.984</td>
<td>1.019</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1479164113490179">
<p>IFG: impaired fasting glucose; IGT: impaired glucose tolerance; CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; DM: diabetes mellitus.</p>
</fn>
<fn id="table-fn3-1479164113490179">
<p>Significant results are given in boldface.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1479164113490179" position="float">
<label>Table 2.</label>
<caption>
<p>Adiponectin dependence from extent of CHD (minor CHD, 1-VD and 2- or 3-VD compared to no CHD).</p>
</caption>
<graphic alternate-form-of="table2-1479164113490179" xlink:href="10.1177_1479164113490179-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="4">Overall</th>
<th align="left" colspan="4">Male</th>
<th align="left" colspan="4">Female</th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)</th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)</th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)</th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="7">Minor CHD</td>
<td>Intercept</td>
<td colspan="4">0.000</td>
<td colspan="4">0.049</td>
<td colspan="4">0.003</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>0.063</td>
<td>0.973</td>
<td>0.946</td>
<td>1.001</td>
<td>0.949</td>
<td>0.998</td>
<td>0.932</td>
<td>1.068</td>
<td>0.201</td>
<td>0.975</td>
<td>0.939</td>
<td>1.013</td>
</tr>
<tr>
<td>Age</td>
<td>0.000</td>
<td>1.098</td>
<td>1.060</td>
<td>1.138</td>
<td>0.151</td>
<td>1.050</td>
<td>0.982</td>
<td>1.123</td>
<td>0.000</td>
<td>1.124</td>
<td>1.073</td>
<td>1.178</td>
</tr>
<tr>
<td>BMI</td>
<td>0.450</td>
<td>1.030</td>
<td>0.955</td>
<td>1.110</td>
<td>0.075</td>
<td>1.185</td>
<td>0.983</td>
<td>1.427</td>
<td>0.708</td>
<td>1.017</td>
<td>0.932</td>
<td>1.110</td>
</tr>
<tr>
<td>HDL</td>
<td>0.422</td>
<td>0.754</td>
<td>0.379</td>
<td>1.502</td>
<td>0.351</td>
<td>2.257</td>
<td>0.408</td>
<td>12.495</td>
<td>0.094</td>
<td>0.394</td>
<td>0.132</td>
<td>1.172</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.677</td>
<td>1.103</td>
<td>0.695</td>
<td>1.750</td>
<td>0.605</td>
<td>0.840</td>
<td>0.434</td>
<td>1.627</td>
<td>0.479</td>
<td>0.761</td>
<td>0.358</td>
<td>1.618</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.005</td>
<td>1.028</td>
<td>1.008</td>
<td>1.048</td>
<td>0.574</td>
<td>1.010</td>
<td>0.975</td>
<td>1.047</td>
<td>0.113</td>
<td>1.017</td>
<td>0.996</td>
<td>1.039</td>
</tr>
<tr>
<td rowspan="7">1-VD</td>
<td>Intercept</td>
<td colspan="4">0.009</td>
<td colspan="4">0.219</td>
<td colspan="4">0.037</td>
</tr>
<tr>
<td>Adiponectin</td>
<td><bold>0.000</bold></td>
<td>0.944</td>
<td>0.915</td>
<td>0.974</td>
<td>0.171</td>
<td>0.953</td>
<td>0.890</td>
<td>1.021</td>
<td>0.100</td>
<td>0.965</td>
<td>0.925</td>
<td>1.007</td>
</tr>
<tr>
<td>Age</td>
<td>0.000</td>
<td>1.078</td>
<td>1.042</td>
<td>1.116</td>
<td>0.312</td>
<td>1.034</td>
<td>0.969</td>
<td>1.102</td>
<td>0.000</td>
<td>1.116</td>
<td>1.064</td>
<td>1.171</td>
</tr>
<tr>
<td>BMI</td>
<td>0.923</td>
<td>1.004</td>
<td>0.932</td>
<td>1.081</td>
<td>0.132</td>
<td>1.151</td>
<td>0.958</td>
<td>1.382</td>
<td>0.775</td>
<td>1.013</td>
<td>0.925</td>
<td>1.110</td>
</tr>
<tr>
<td>HDL</td>
<td>0.218</td>
<td>0.649</td>
<td>0.326</td>
<td>1.291</td>
<td>0.373</td>
<td>2.155</td>
<td>0.398</td>
<td>11.674</td>
<td>0.056</td>
<td>0.320</td>
<td>0.099</td>
<td>1.030</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.242</td>
<td>1.299</td>
<td>0.838</td>
<td>2.015</td>
<td>1.000</td>
<td>1.000</td>
<td>0.538</td>
<td>1.859</td>
<td>0.514</td>
<td>0.773</td>
<td>0.357</td>
<td>1.674</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.012</td>
<td>1.025</td>
<td>1.006</td>
<td>1.045</td>
<td>0.697</td>
<td>1.007</td>
<td>0.972</td>
<td>1.043</td>
<td>0.681</td>
<td>1.005</td>
<td>0.982</td>
<td>1.028</td>
</tr>
<tr>
<td rowspan="7">2-VD or 3-VD</td>
<td>Intercept</td>
<td colspan="4">0.027</td>
<td colspan="4">0.260</td>
<td colspan="4">0.031</td>
</tr>
<tr>
<td>Adiponectin</td>
<td><bold>0.000</bold></td>
<td>0.925</td>
<td>0.898</td>
<td>0.954</td>
<td><bold>0.021</bold></td>
<td>0.924</td>
<td>0.863</td>
<td>0.988</td>
<td>0.228</td>
<td>0.976</td>
<td>0.938</td>
<td>1.015</td>
</tr>
<tr>
<td>Age</td>
<td>0.000</td>
<td>1.084</td>
<td>1.049</td>
<td>1.120</td>
<td>0.200</td>
<td>1.042</td>
<td>0.979</td>
<td>1.109</td>
<td>0.000</td>
<td>1.130</td>
<td>1.079</td>
<td>1.184</td>
</tr>
<tr>
<td>BMI</td>
<td>0.994</td>
<td>1.000</td>
<td>0.931</td>
<td>1.074</td>
<td>0.094</td>
<td>1.166</td>
<td>0.974</td>
<td>1.396</td>
<td>0.871</td>
<td>0.993</td>
<td>0.908</td>
<td>1.085</td>
</tr>
<tr>
<td>HDL</td>
<td>0.001</td>
<td>0.323</td>
<td>0.162</td>
<td>0.643</td>
<td>0.771</td>
<td>1.280</td>
<td>0.242</td>
<td>6.782</td>
<td>0.002</td>
<td>0.158</td>
<td>0.050</td>
<td>0.502</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.844</td>
<td>1.044</td>
<td>0.681</td>
<td>1.600</td>
<td>0.432</td>
<td>0.784</td>
<td>0.427</td>
<td>1.439</td>
<td>0.453</td>
<td>0.752</td>
<td>0.357</td>
<td>1.585</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.000</td>
<td>1.040</td>
<td>1.020</td>
<td>1.059</td>
<td>0.285</td>
<td>1.019</td>
<td>0.985</td>
<td>1.054</td>
<td>0.143</td>
<td>1.016</td>
<td>0.995</td>
<td>1.038</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1479164113490179">
<p>CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; CHD: coronary heart disease; exp(B): exponentiation of the B coefficient; 1-VD: single-vessel disease; 2-VD: double-vessel disease; 3-VD: triple-vessel disease.</p>
</fn>
<fn id="table-fn5-1479164113490179">
<p>Significant results are given in boldface.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>NYHA II compared to I indicated, in the overall analysis, significances in adiponectin, age and BMI (all OR &gt; 1). Those three variables and creatinine showed significant results in the male patient group (all OR &gt; 1). No factor had a significant influence on the female patient group. On comparing NYHA III and I levels, adiponectin, age and BMI presented significant effect in the overall and in the male group (all OR &gt; 1). Adiponectin, age and creatinine had significant impact in the female group (all OR &gt; 1) (for results, see <xref ref-type="table" rid="table3-1479164113490179">Table 3</xref>).</p>
<table-wrap id="table3-1479164113490179" position="float">
<label>Table 3.</label>
<caption>
<p>Adiponectin dependence from NYHA state (II and III compared to I) each with confounders of age, BMI, HDL, triglyceride, creatinine and split into men/women.</p>
</caption>
<graphic alternate-form-of="table3-1479164113490179" xlink:href="10.1177_1479164113490179-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="4">Overall<hr/></th>
<th align="left" colspan="4">Male<hr/></th>
<th align="left" colspan="4">Female<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)<hr/></th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)<hr/></th>
<th align="left">Significance</th>
<th align="left">Odds ratio</th>
<th align="left" colspan="2">95% CI for exp(B)<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
<th/>
<th/>
<th align="left">Lower bound</th>
<th align="left">Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="7">NYHA II</td>
<td>Intercept</td>
<td colspan="4">0.000</td>
<td colspan="4">0.000</td>
<td colspan="4">0.500</td>
</tr>
<tr>
<td>Adiponectin</td>
<td><bold>0.004</bold></td>
<td>1.039</td>
<td>1.012</td>
<td>1.066</td>
<td><bold>0.050</bold></td>
<td>1.036</td>
<td>1.000</td>
<td>1.074</td>
<td>0.159</td>
<td>1.030</td>
<td>0.989</td>
<td>1.072</td>
</tr>
<tr>
<td>Age</td>
<td>0.006</td>
<td>1.029</td>
<td>1.008</td>
<td>1.050</td>
<td>0.049</td>
<td>1.025</td>
<td>1.000</td>
<td>1.051</td>
<td>0.157</td>
<td>1.029</td>
<td>0.989</td>
<td>1.071</td>
</tr>
<tr>
<td>BMI</td>
<td>0.000</td>
<td>1.097</td>
<td>1.045</td>
<td>1.151</td>
<td>0.000</td>
<td>1.123</td>
<td>1.055</td>
<td>1.194</td>
<td>0.228</td>
<td>1.050</td>
<td>0.970</td>
<td>1.137</td>
</tr>
<tr>
<td>HDL</td>
<td>0.587</td>
<td>1.149</td>
<td>0.696</td>
<td>1.899</td>
<td>0.111</td>
<td>1.685</td>
<td>0.888</td>
<td>3.199</td>
<td>0.102</td>
<td>0.449</td>
<td>0.172</td>
<td>1.172</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.840</td>
<td>1.023</td>
<td>0.818</td>
<td>1.281</td>
<td>0.908</td>
<td>1.014</td>
<td>0.794</td>
<td>1.296</td>
<td>0.827</td>
<td>1.076</td>
<td>0.556</td>
<td>2.083</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.081</td>
<td>1.008</td>
<td>0.999</td>
<td>1.017</td>
<td>0.019</td>
<td>1.014</td>
<td>1.002</td>
<td>1.026</td>
<td>0.789</td>
<td>1.003</td>
<td>0.984</td>
<td>1.022</td>
</tr>
<tr>
<td rowspan="7">NYHA III</td>
<td>Intercept</td>
<td colspan="4">0.000</td>
<td colspan="4">0.000</td>
<td colspan="4">0.003</td>
</tr>
<tr>
<td>Adiponectin</td>
<td><bold>0.000</bold></td>
<td>1.090</td>
<td>1.051</td>
<td>1.131</td>
<td><bold>0.000</bold></td>
<td>1.105</td>
<td>1.050</td>
<td>1.164</td>
<td><bold>0.033</bold></td>
<td>1.061</td>
<td>1.005</td>
<td>1.120</td>
</tr>
<tr>
<td>Age</td>
<td>0.002</td>
<td>1.064</td>
<td>1.024</td>
<td>1.105</td>
<td>0.031</td>
<td>1.053</td>
<td>1.005</td>
<td>1.104</td>
<td>0.040</td>
<td>1.079</td>
<td>1.004</td>
<td>1.161</td>
</tr>
<tr>
<td>BMI</td>
<td>0.000</td>
<td>1.156</td>
<td>1.074</td>
<td>1.245</td>
<td>0.001</td>
<td>1.176</td>
<td>1.067</td>
<td>1.295</td>
<td>0.149</td>
<td>1.095</td>
<td>0.968</td>
<td>1.239</td>
</tr>
<tr>
<td>HDL</td>
<td>0.056</td>
<td>0.387</td>
<td>0.146</td>
<td>1.025</td>
<td>0.120</td>
<td>0.353</td>
<td>0.095</td>
<td>1.310</td>
<td>0.299</td>
<td>0.432</td>
<td>0.088</td>
<td>2.107</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.745</td>
<td>0.934</td>
<td>0.618</td>
<td>1.411</td>
<td>0.573</td>
<td>0.873</td>
<td>0.546</td>
<td>1.398</td>
<td>0.889</td>
<td>1.076</td>
<td>0.386</td>
<td>3.000</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.069</td>
<td>1.009</td>
<td>0.999</td>
<td>1.019</td>
<td>0.058</td>
<td>1.013</td>
<td>1.000</td>
<td>1.026</td>
<td>0.017</td>
<td>1.031</td>
<td>1.006</td>
<td>1.057</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1479164113490179">
<p>CI: confidence interval; BMI: body mass index; HDL: high-density lipoprotein; exp(B): exponentiation of the B coefficient; NYHA: New York Heart Association.</p>
</fn>
<fn id="table-fn7-1479164113490179">
<p>Significant results are given in boldface.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section16-1479164113490179" sec-type="conclusions">
<title>Conclusion</title>
<p>In the literature, there are data about decreased adiponectin levels in DM and CHD.<sup><xref ref-type="bibr" rid="bibr1-1479164113490179">1</xref>,<xref ref-type="bibr" rid="bibr7-1479164113490179">7</xref>,<xref ref-type="bibr" rid="bibr8-1479164113490179">8</xref></sup> Low adiponectin levels have been associated with insulin resistance as a key finding in type 2 diabetes and CHD.<sup><xref ref-type="bibr" rid="bibr18-1479164113490179">18</xref>,<xref ref-type="bibr" rid="bibr19-1479164113490179">19</xref></sup> Along this line, our study found higher adiponectin levels in patients with suspected CHD and NGT compared to patients with newly diagnosed IGT and type 2 diabetes. In multivariate analysis, this difference holds true for women but not for men.</p>
<p>Although these patients without known diabetes may be expected in an early phase of their disease, many of them had already progressed CHD from catheterization findings. Again in line with the known literature,<sup><xref ref-type="bibr" rid="bibr20-1479164113490179">20</xref></sup> we found a stepwise decrease in adiponectin levels with progressing CHD in catheterization findings. Currently, it is not clear whether adiponectin is a real protective factor in the coronary disease process or more a bystander reflecting other risk factors. In our population, we found a negative correlation to other risk factors such as smoking habits, obesity, glucose intolerance or triglycerides (or positive correlation to the protective HDL cholesterol). Against expectations, we also found a positive correlation to LDL and whole cholesterol. The high correlation to HDL cholesterol is remarkable and in agreement with previous data.<sup><xref ref-type="bibr" rid="bibr21-1479164113490179">21</xref></sup> But there is direct evidence for protective influence of adiponectin on cardiac function in the literature.<sup><xref ref-type="bibr" rid="bibr22-1479164113490179">22</xref>,<xref ref-type="bibr" rid="bibr23-1479164113490179">23</xref></sup> In multivariate analysis, sex differences were obvious – the significant correlation between adiponectin levels and extent of coronary disease was shown for male but not for female patients possibly due to age being a main confounder in female patients. In contrast, HDL cholesterol was a main confounder in both sexes in agreement with the high correlation described above.<sup><xref ref-type="bibr" rid="bibr21-1479164113490179">21</xref></sup></p>
<p>Arguing against a pure protective role of adiponectin in CHD, we found a positive correlation of adiponectin to progressing heart failure as judged by NYHA state, NT-proBNP or EF. Similar findings were reported.<sup><xref ref-type="bibr" rid="bibr13-1479164113490179">13</xref>,<xref ref-type="bibr" rid="bibr24-1479164113490179">24</xref><xref ref-type="bibr" rid="bibr25-1479164113490179"/>–<xref ref-type="bibr" rid="bibr26-1479164113490179">26</xref></sup> It is not clear whether this increase in adiponectin levels may be a counter-regulatory process or a pathophysiological detrimental factor. It has been described that NT-proBNP is able to stimulate adiponectin secretion in adipocytes.<sup><xref ref-type="bibr" rid="bibr25-1479164113490179">25</xref></sup> Also, in our study, there is a positive correlation of NT-proBNP and adiponectin levels as described elsewhere.<sup><xref ref-type="bibr" rid="bibr27-1479164113490179">27</xref>,<xref ref-type="bibr" rid="bibr28-1479164113490179">28</xref></sup> Moreover, there is evidence of a local adiponectin secretion in cardiomyocytes, but this secretion seems to be much less than from adipocytes and not measurable in blood plasma.<sup><xref ref-type="bibr" rid="bibr29-1479164113490179">29</xref>,<xref ref-type="bibr" rid="bibr30-1479164113490179">30</xref></sup> Some authors blame cachexia in heart failure for increasing adiponectin levels,<sup><xref ref-type="bibr" rid="bibr28-1479164113490179">28</xref></sup> but this reason is not likely in our patients with early and mild heart failure NYHA II/III or I.</p>
<p>The strength of our study is a large population of clinically well-characterized patients attending a routine catheterization laboratory investigation without previous known IGT. Therefore, these patients seemed to be in an early phase of metabolic–vascular disease although already progressed vascular findings were seen in catheterization. We confirm a negative correlation of adiponectin levels with both progressing glucose intolerance and cardiovascular disease. The interpretation of adiponectin levels for individual patients may be confusing, however, by increase in the adiponectin levels even in earlier states of heart failure (NYHA II or III).</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank the staff of the study unit of the Praxisklinik Herz und Gefässe and of the Central Laboratory of the Municipal Hospital of Dresden-Neustadt for organizing patient recruitment and lab analyses.</p>
<p>A.A.G., R.D., S.S., J.S., I.A.Z., O.S., and T.L. are responsible for conception and design, analysis and interpretation of the data; drafting the article; revising the article and for final approval of the version to be published. B.U. is responsible for statistical analysis of data and revising the article critically for important intellectual content. A.B. is responsible for laboratory analysis and also revising the article critically for important intellectual content</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>I.A.Z. and V.L. are employees of Roche Diagnostics GmbH, which markets assays of biomarkers for cardiovascular disease such as NT-proBNP. There are no other conflicting interests to declare.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The ‘Silent diabetes study’ was sponsored by an unrestricted grant of Roche Diagnostics GmbH.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1479164113490179">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karatergiou</surname><given-names>K</given-names></name>
<name><surname>Mohamed-Ali</surname><given-names>V</given-names></name>
<name><surname>Jahangiri</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adiponectin for prediction of cardiovascular risk?</article-title> <source>Br J Diabetes Vasc Dis</source> <year>2009</year>; <volume>9</volume>: <fpage>150</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr2-1479164113490179">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scherer</surname><given-names>PE</given-names></name>
<name><surname>Williams</surname><given-names>S</given-names></name>
<name><surname>Fogliano</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>A novel serum protein similar to C1q, produced exclusively in adipocytes</article-title>. <source>J Biol Chem</source> <year>1995</year>; <volume>270</volume>: <fpage>26746</fpage>–<lpage>26749</lpage>.</citation>
</ref>
<ref id="bibr3-1479164113490179">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>E</given-names></name>
<name><surname>Liang</surname><given-names>P</given-names></name>
<name><surname>Spiegelman</surname><given-names>BM</given-names></name>
</person-group>. <article-title>AdipoQ is a novel adipose-specific gene dysregulated in obesity</article-title>. <source>J Biol Chem</source> <year>1996</year>; <volume>271</volume>: <fpage>10697</fpage>–<lpage>10703</lpage>.</citation>
</ref>
<ref id="bibr4-1479164113490179">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>K</given-names></name>
<name><surname>Okubo</surname><given-names>K</given-names></name>
<name><surname>Shimomura</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant gene transcript 1)</article-title>. <source>Biochem Biophys Res Commun</source> <year>1996</year>; <volume>221</volume>: <fpage>286</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr5-1479164113490179">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakano</surname><given-names>Y</given-names></name>
<name><surname>Tobe</surname><given-names>T</given-names></name>
<name><surname>Choi-Miura</surname><given-names>NH</given-names></name><etal/>
</person-group>. <article-title>Isolation and characterization of GFP28, a novel gelatin-binding protein</article-title>. <source>J Biochem</source> <year>1996</year>; <volume>120</volume>: <fpage>803</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr6-1479164113490179">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spranger</surname><given-names>J</given-names></name>
<name><surname>Kroke</surname><given-names>A</given-names></name>
<name><surname>Mohlig</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adiponectin and protection against type 2 diabetes mellitus</article-title>. <source>Lancet</source> <year>2003</year>; <volume>361</volume>: <fpage>226</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr7-1479164113490179">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ouchi</surname><given-names>N</given-names></name>
<name><surname>Kihara</surname><given-names>S</given-names></name>
<name><surname>Arita</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin</article-title>. <source>Circulation</source> <year>1999</year>; <volume>100</volume>: <fpage>2473</fpage>–<lpage>2476</lpage>.</citation>
</ref>
<ref id="bibr8-1479164113490179">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pischon</surname><given-names>T</given-names></name>
<name><surname>Girman</surname><given-names>CJ</given-names></name>
<name><surname>Hotamisligil</surname><given-names>GS</given-names></name><etal/>
</person-group>. <article-title>Plasma adiponectin levels and risk of myocardial infarction in men</article-title>. <source>JAMA</source> <year>2004</year>; <volume>291</volume>: <fpage>1730</fpage>–<lpage>1737</lpage>.</citation>
</ref>
<ref id="bibr9-1479164113490179">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>SR</given-names></name>
<name><surname>Sabatine</surname><given-names>MS</given-names></name>
<name><surname>Wiviott</surname><given-names>SD</given-names></name><etal/>
</person-group>. <article-title>Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22)</article-title>. <source>Am Heart J</source> <year>2011</year>; <volume>161</volume>: <fpage>1147</fpage>–<lpage>1155</lpage>.</citation>
</ref>
<ref id="bibr10-1479164113490179">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindberg</surname><given-names>S</given-names></name>
<name><surname>Pedersen</surname><given-names>SH</given-names></name>
<name><surname>Mogelvang</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source> <year>2012</year>; <volume>109</volume>: <fpage>492</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr11-1479164113490179">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kistorp</surname><given-names>C</given-names></name>
<name><surname>Faber</surname><given-names>J</given-names></name>
<name><surname>Galatius</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure</article-title>. <source>Circulation</source> <year>2005</year>; <volume>112</volume>: <fpage>1756</fpage>–<lpage>1762</lpage>.</citation>
</ref>
<ref id="bibr12-1479164113490179">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsutamato</surname><given-names>T</given-names></name>
<name><surname>Tanaka</surname><given-names>T</given-names></name>
<name><surname>Sakai</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure</article-title>. <source>Eur Heart J</source> <year>2007</year>; <volume>28</volume>: <fpage>1723</fpage>–<lpage>1730</lpage>.</citation>
</ref>
<ref id="bibr13-1479164113490179">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wannamethee</surname><given-names>SG</given-names></name>
<name><surname>Whincup</surname><given-names>PH</given-names></name>
<name><surname>Lennon</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure</article-title>. <source>Arch Intern Med</source> <year>2007</year>; <volume>167</volume>: <fpage>1510</fpage>–<lpage>1517</lpage>.</citation>
</ref>
<ref id="bibr14-1479164113490179">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doerr</surname><given-names>R</given-names></name>
<name><surname>Hoffmann</surname><given-names>U</given-names></name>
<name><surname>Otter</surname><given-names>W</given-names></name><etal/>
</person-group>. <article-title>Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography</article-title>. <source>Diabetologia</source> <year>2011</year>; <volume>54</volume>: <fpage>2923</fpage>–<lpage>2930</lpage>.</citation>
</ref>
<ref id="bibr15-1479164113490179">
<label>15.</label>
<citation citation-type="book">
<collab>World Health Organization</collab>. <source>Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO Department of Noncommunicable Disease Surveillance</publisher-name>, <year>1999</year>.</citation>
</ref>
<ref id="bibr16-1479164113490179">
<label>16.</label>
<citation citation-type="journal">
<collab>American Diabetes Association</collab>. <article-title>Standards of medical care in diabetes</article-title>. <source>Diabetes Care</source> <year>2004</year>; <volume>27</volume>(<supplement>Suppl. 1</supplement>): <fpage>S15</fpage>–<lpage>S34</lpage>.</citation>
</ref>
<ref id="bibr17-1479164113490179">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reiber</surname><given-names>JHC</given-names></name>
<name><surname>Serruys</surname><given-names>PW</given-names></name>
<name><surname>Kooimann</surname><given-names>CJ</given-names></name><etal/>
</person-group>. <article-title>Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineograms</article-title>. <source>Circulation</source> <year>1985</year>; <volume>71</volume>: <fpage>280</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr18-1479164113490179">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hotta</surname><given-names>K</given-names></name>
<name><surname>Funahashi</surname><given-names>T</given-names></name>
<name><surname>Bodkin</surname><given-names>NL</given-names></name><etal/>
</person-group>. <article-title>Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression of type 2 diabetes in rhesus monkeys</article-title>. <source>Diabetes</source> <year>2001</year>; <volume>50</volume>: <fpage>1126</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr19-1479164113490179">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weyer</surname><given-names>C</given-names></name>
<name><surname>Funahashi</surname><given-names>T</given-names></name>
<name><surname>Tanaka</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia</article-title>. <source>J Clin Endocrinol Metab</source> <year>2001</year>; <volume>86</volume>: <fpage>1930</fpage>–<lpage>1935</lpage>.</citation>
</ref>
<ref id="bibr20-1479164113490179">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Von Eynatten</surname><given-names>M</given-names></name>
<name><surname>Schneider</surname><given-names>JG</given-names></name>
<name><surname>Humpert</surname><given-names>PM</given-names></name><etal/>
</person-group>. <article-title>Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men</article-title>. <source>J Am Coll Cardiol</source> <year>2006</year>; <volume>47</volume>: <fpage>2124</fpage>–<lpage>2226</lpage>.</citation>
</ref>
<ref id="bibr21-1479164113490179">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zietz</surname><given-names>B</given-names></name>
<name><surname>Herfarth</surname><given-names>H</given-names></name>
<name><surname>Paul</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Adiponectin represents an independent cardiovascular risk factor predicting HDL-cholesterol levels in type 2 diabetes</article-title>. <source>FEBS Lett</source> <year>2003</year>; <volume>545</volume>: <fpage>103</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr22-1479164113490179">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shibata</surname><given-names>R</given-names></name>
<name><surname>Ouchi</surname><given-names>N</given-names></name>
<name><surname>Ito</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adiponectin-mediated modulation of hypertrophic signals in the heart</article-title>. <source>Nat Med</source> <year>2004</year>; <volume>10</volume>: <fpage>1384</fpage>–<lpage>1389</lpage>.</citation>
</ref>
<ref id="bibr23-1479164113490179">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shibata</surname><given-names>R</given-names></name>
<name><surname>Izumiya</surname><given-names>Y</given-names></name>
<name><surname>Sato</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>Adiponectin protects against the development of systolic dysfunction following myocardial function</article-title>. <source>J Mol Cell Cardiol</source> <year>2007</year>; <volume>42</volume>: <fpage>1065</fpage>–<lpage>1074</lpage>.</citation>
</ref>
<ref id="bibr24-1479164113490179">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shinmura</surname><given-names>K</given-names></name>
</person-group>. <article-title>Is adiponectin a bystander or a mediator in heart failure? The tangled thread of a good-natured adipokine in aging and cardiovascular disease</article-title>. <source>Heart Fail Rev</source> <year>2010</year>; <volume>15</volume>: <fpage>457</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr25-1479164113490179">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsukamato</surname><given-names>O</given-names></name>
<name><surname>Fujita</surname><given-names>M</given-names></name>
<name><surname>Kato</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2009</year>; <volume>53</volume>: <fpage>2070</fpage>–<lpage>2077</lpage>.</citation>
</ref>
<ref id="bibr26-1479164113490179">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singer</surname><given-names>JR</given-names></name>
<name><surname>Palmas</surname><given-names>W</given-names></name>
<name><surname>Teresi</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Adiponectin and all-cause mortality in elderly people with type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>2012</year>; <volume>35</volume>: <fpage>1858</fpage>–<lpage>1863</lpage>.</citation>
</ref>
<ref id="bibr27-1479164113490179">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haugen</surname><given-names>E</given-names></name>
<name><surname>Furukawa</surname><given-names>Y</given-names></name>
<name><surname>Isic</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: a hospital cohort study</article-title>. <source>Int J Cardiol</source> <year>2008</year>; <volume>125</volume>: <fpage>216</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr28-1479164113490179">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McEntegart</surname><given-names>MB</given-names></name>
<name><surname>Awede</surname><given-names>B</given-names></name>
<name><surname>Petrie</surname><given-names>MC</given-names></name><etal/>
</person-group>. <article-title>Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide</article-title>. <source>Eur Heart J</source> <year>2007</year>; <volume>28</volume>: <fpage>829</fpage>–<lpage>835</lpage>.</citation>
</ref>
<ref id="bibr29-1479164113490179">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ding</surname><given-names>G</given-names></name>
<name><surname>Qin</surname><given-names>Q</given-names></name>
<name><surname>He</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Adiponectin and its receptors are expressed in adult ventricular cardiomyocytes and upregulated by activation of peroxisome proliferator-activated receptor gamma</article-title>. <source>J Mol Cell Cardiol</source> <year>2007</year>; <volume>43</volume>: <fpage>73</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr30-1479164113490179">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pineiro</surname><given-names>R</given-names></name>
<name><surname>Iglesias</surname><given-names>MJ</given-names></name>
<name><surname>Gallego</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Adiponectin is synthesized and secreted by human and murine cardiomyocytes</article-title>. <source>FEBS Lett</source> <year>2005</year>; <volume>579</volume>: <fpage>5163</fpage>–<lpage>5169</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>